Acrivon Therapeutics reported its Q1 2026 financial results, showing a net loss of $19.0 million, consistent R&D spending, and $97.7 million in cash plus $7.3 million from recent financing, funding operations into Q3 2027. The company is advancing two key cancer drug candidates: ACR-368 for serous endometrial cancer, with a planned interim Phase 2b data update in late 2026, and ACR-2316, showing promising activity in lung cancers with favorable safety. Upcoming milestones include readiness for a Phase 3 trial of ACR-368 combined with PD-1 therapy and further clinical data for ACR-2316. These developments position Acrivon for potential value inflection in oncology drug development.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
